Bioventus (BVS) Research & Development (2020 - 2026)

Bioventus' Research & Development history runs 7 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• Quarterly Research & Development fell 18.07% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 19.3% YoY) and the FY2025 annual result came in at $12.1 million, down 13.17% from the prior year.
• Research & Development was $2.5 million for Q1 2026 at Bioventus, down from $3.0 million in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q2 2022 and bottomed at $2.5 million in Q1 2026.
• A 5-year average of $3.9 million and a median of $3.3 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development soared 631.57% — and 2023, when it sank 46.62%.
• Bioventus' Research & Development stood at $5.9 million in 2022, then tumbled by 45.14% to $3.3 million in 2023, then gained by 0.28% to $3.3 million in 2024, then slipped by 8.07% to $3.0 million in 2025, then fell by 17.96% to $2.5 million in 2026.
• Business Quant data shows BVS's Research & Development at $2.5 million in Q1 2026, $3.0 million in Q4 2025, and $2.9 million in Q3 2025.